SmithKline shoots up

Article Abstract:

SmithKline Beecham's share price rose in Aug 1996. Five stockbrokers from a sample of six rate the shares a buy, while one rates the shares a hold. Buyers include Goldman Sachs which sees the company's margins from pharmaceutical products as strong, and the company's sales growth as superior. The holder is Lehman Brothers which is concerned about SmithKline Beecham's cash generation. Over the longer term the company should benefit from investments in genetic science.

SmithKline Beecham Corp. (Philadelphia, Pennsylvania), SBH

---

Sanofi-Synthelabo

Article Abstract:

French pharmaceutical firm Sanofi-Synthelabo is Europe's fastest-growing drugs group and its shares, although not cheap, are seen as a good buy. The firm has three blockbuster drugs, including its anti-stroke drug Plavix, which, when combined with aspirin, is thought to slash heart attack risk.

Sanofi-Synthelabo

---

Withdrawal symptoms

Article Abstract:

European pharmaceutical shares' strong performance since the terrorist attacks on the US reflect their defensive qualities. However, the industry faces its own challenges, including the growing trend towards litigation and a slowdown in new product development.

Industry Overview

Similar abstracts:

• Abstracts: Toplin & Assocs. Strategy Assocs. Schneider & Assocs
• Abstracts: Vitkovice sees a loss. Vitkovice is awarded ship contracts. Vitkovice with a high loss
• Abstracts: Small charities stock up. Everybody's rolling out the red carpet. Time to change your toothpaste?
• Abstracts: Entertainment & media stocks. Media & entertainment stocks
• Abstracts: Softening up the market. Misys. Catch a falling knife

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.